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The  HLA-DR  or  human  Ia  molecules  are  major  histocompatibility  complex 
(MHC)-encoded polymorphic cell surface glycoproteins made up of two noncovalently 
linked subunits of 34-36,000  (a)  and  26-29,000  (fl)  mol wt, respectively, which are 
believed to play an important role in the homeostasis of the immune system (reviewed 
in  1).  Recent  studies have shown  that  the human  Ia molecular pool is composed of 
structurally distinct subsets of molecules. Some of these,  like the NG1  and the NG2 
subsets  (2-4)  are present  in  all individuals and  constitute probably two  isotypes of 
HLA-DR  molecules. Some others of more restricted polymorphism, like DC-1  (5, 6), 
BR 4 ×  7 (7), and I-LR1  (8) molecules, are present only in certain individuals and are 
believed to be coded for by genes in close linkage disequilibrium with the genes coding 
for the classic polymorphic HLA-DR molecules. The existence of structurally different 
families of Ia molecules raises the question of whether a  given biological function may 
be related to a  specific Ia subset. 
One of the approaches to study the relationship between structure and function is 
to generate cell variants that  have  lost the expression of the relevant structure  and 
then to analyze whether the absence of such structure correlates with an alteration of 
a  specific function.  As a  first step toward this goal we have isolated cell variants by 
immunoselection  using either anti-NG1  or anti-NG2  monoclonal  antibodies  (Mab) 
and complement  (C). This report describes the generation as well as the phenotypic 
characterization of HLA-DR-negative variants selected from  the human  B  cell line 
Raji. 
Materials  and  Methods 
Monoclonal antibodies.  The following Mab were used in the present study: Dl-12 (anti-NG1) 
(2-4), BT 2.2 (anti-NG2) (4), BT 3/4 (anti-DC-1) (6), and W6.32 (anti-HLA-A, B, C common) 
(9). 
Selection procedure.  Mutagenesis was performed as described by Kavathas et al. (10). Briefly, 
5  ×  106  Raji cells were irradiated with 300  rad and  then cultured in  24-well Costar plates 
(Costar, Data Packaging~ Cambridge, MA) precoated with irradiated mouse macrophages, at 
a concentration of 1 ×  10/ml. After 3-4 d the cells were immunoselected by adding a saturating 
dose of either D1-12 or BT-2.2 Mab and C. The addition of specific anti-Ia Mab and C  was 
repeated every 4  d  over a  period of 1 mo.  Cells surviving the treatment were cloned under 
limiting dilution conditions in the presence of irradiated mouse macrophages. Representative 
clones from three separate immunoselection experiments were chosen for further analysis. 
Flow microfluorometric analysis of stained cells.  Cells were harvested from cultures in exponential 
phase of growth, washed twice with cold medium, and resuspended at a concentration of 5 × 
106/ml. Cell suspension (0.1 ml) was incubated for 45 min at 4°C with 0.1 ml of a saturating 
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dose of Mab. After washing, the cells were then incubated with 0.1 ml fluorescein isothiocyanate 
(FITC)-coupled goat anti-mouse Ig (Nordic, Tilburg, Netherlands)  for 45 min in ice. The cells 
were then analyzed by flow cytometry on the fluorescence-activated cell sorter (FACS II; B-D 
FACS Systems, Becton, Dickinson & Co., Sunnyvale, CA). 
Radiobinding analysis.  The binding test was performed as previously described (2). Briefly,  1 
×  10  ~ cells were incubated for 1 h at 4°C with 50 #1 of various Mab dilutions. The amount of 
antibody bound was assessed by adding i2~I-labeled IgG rabbit anti-mouse F(ab')2. 
Results  and  Discussion 
Three  cloned  cell  variants,  RJ2.2.5,  RJD1.2,  and  RJD1.3,  derived  from  three 
independent  selection  experiments,  were  analyzed  in  detail  in  this  study.  The  first 
one, RJ2.2.5,  was derived  after selection with  the BT 2.2 Mab  (anti-NG2),  and  the 
other  two  clones,  RJD1.2  and  RJD1.3,  after  selection  with  the  D1-12  Mab  (anti- 
NGI). 
Fig.  1 shows the flow microfluorometric analysis of the RJ2.2.5  variant  cells after 
cell  surface  staining  with  various  Mab.  It  can  be  seen  that  the  RJ2.2.5  cells  were 
negative  for the surface  expression  of both  Dl-12  and  BT  2.2  specific epitopes.  To 
assess whether other molecules encoded by genes within  the human MHC  were also 
affected by the immunoselection,  we analyzed the expression of DC-1  molecules  (5), 
which are normally present  on the cell surface of Raji cells, as well as the expression 
of HLA-A,  B,  and  C  structures.  Two  Mab,  BT  3/4  (anti-DC-1)  (6)  and  W6.32, 
directed against a determinant common to HLA-A, B, and C  antigens (9), were used. 
As shown in Fig.  1, no detectable BT 3/4-specific epitopes were found in the variant 
RJ2.2.5,  whereas  the  expression  of HLA-A,  B,  and  C  common  determinants,  as 
detected  by W6.32  Mab,  was  not  affected.  Similar  results  were  obtained  with  the 
other two cell variants,  RJD1  and RJD1.3. 
These results were confirmed by quantitative  binding studies  of the various  Mab 
using 125I-labeled anti-mouse F(ab')2 antibodies.  In Fig. 2, it can be seen that even at 
concentrations of Mab  giving plateau  binding values on the parental  Raji cells, the 
three  variants  were  negative  for Dl-12,  BT  2.2,  and  BT  3/4  Mab.  Conversely,  no 
significant differences were observed in the amount of W6.32 specific epitopes present 
in the three variants as compared with Raji cells. 
In addition,  flow microfluorometrie analysis by using FITC-coupled F(ab')2  goat 
anti-human Ig showed no appreciable difference in the amount of surface Ig expressed 
by the three variants as compared with the parental  Raji cells (data not shown). 
Furthermore, as assessed by a rosette assay using ox erythrocytes coated with rabbit 
IgG anti-ox (11), both Raji cells and the three Ia-negative cell variants were found to 
express no detectable Fc receptors for IgG (data not shown). 
When lysates from [aSS]methionine-biosynthetically labeled cells were immunopre- 
cipitated  by the various  anti-Ia Mab  used  in this  study and by a  polyvalent rabbit 
anti-human Iap  34,29 (gift of Dr F. Buchegger, Dept. of Biochemistry, University of 
Lausanne),  no detectable  Ia-specific bands  were  found in  any of the  three  variants 
(data not shown). 
Collectively, these results  indicate that  the three  variants  have concomitantly lost 
the  expression  of not  only the  Ia  molecular  subset  against  which  they  have  been 
specifically selected, but also of other Ia subsets that are structurally distinct  from the 
latter.  Moreover, the loss of expression  of Ia molecules was not accompanied by the 
loss of expression of other cell surface markers like HLA-A, B, C  molecules or surface ROBERTO  S.  ACCOLLA  BRIEF  DEFINITIVE REPORT  1055 
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FIc.  1.  Flow microfluorimetric analysis  of Raji cells after immunoselection with distinct anti-Ia 
Mab and C. The upper series of panels (first and third) shows the flow microfluorometric pattern 
of the parental Raji cells when assayed  for D1-12, BT 2.2, BT 3/4, and W6.32 Mab, respectively, 
followed  by the detecting reagent, FITC-coupled goat anti-mouse Ig. The lower series of panels 
(second and fourth)  shows the flow microfluorimetric pattern of RJ2.2.5, a cloned cell variant, when 
assayed with the same Mab as above. "a" represents  the negative control, which in the case of D1- 
12, BT 2.2, and BT 3/4 Mab is the reactivity pattern of such antibodies on the Ia-negative human 
T cell line MOLT-4, whereas in the case of W6.32 Mab (anti-HLA-A, B, C common) is represented 
by the reactivity pattern of PX63 culture fluid on the two distinct cell lines. Values are expressed in 
arbitrary units (a.u.). 
Ig. To  discuss possible  explanations  of the above results,  several considerations  must 
be made. 
The  HLA-DR  polymorphism  is carried by the/3 subunit  (4,  5,  12).  NG1  and  NG2 
Ia subsets are present in all individuals irrespective of their DR  phenotype.  Both NG 1 
and  NG2  subsets  carry allelic polyrnorphism  that  is confined to their/3  subunits  (5). 
When  typed  for HLA  speeificities, RJ2.2.5,  RJD1.2, and  RJD1.3  appear  to have lost 
both  DR  haplotypic  markers  (3  and  W6)  present  in  the  heterozygous  parental  cell 
line  Raji  as  well  as  DC-1  markers;  on  the  contrary,  HLA  typing  for  A,  B,  and  C 1056  ROBERTO  S.  ACCOLLA  BRIEF  DEFINITIVE  REPORT 
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FIG. 2.  Quantitation  of distinct Ia epitopes and common HLA-A, B, C epitopes in immunoselected 
Raji cell variants. The binding test was performed as described in Materials and Methods. Each 
point represents the mean of duplicate values. G: parental Raji cells; I: RJ2.2.5 cells; A: RJD1.2 
cells; V: RJD1.3 cells; X: binding values of PX63 ascltic fluid on Raji cells which we assume as 
negative controL. Abscissa: reciprocal Mab ascitic fluid dilution used; ordinate: total counts bound 
of 12SI-labeled  rabbit anti-mouse F(ab')2. 
specificities  was  the  same  as  that  of  the  parental  Raji  cells  (J.  Vives,  personal 
communication). 
Taken together these results are reminiscent of those obtained by Gladstone and 
Pious (13), who isolated DR  1,3-negative variants by using an alloantiserum directed 
against  only the  DR  1  haplotype  of a  heterozygous  DR  1,3  B  cell  line.  Ionizing 
radiations are known to induce preferentially deletions ranging in size from intragenic 
deletions to losses of relevant portions of a chromosome (14). If this is the mechanism 
by which  our  variants have  been generated,  it  is  necessary to  postulate a  massive 
deletion of the  different j~ chain coding genes located,  at  least  for  NG1  and  NG2 
subsets, in the two copies of chromosome 6. 
The  variants could  be  the  result  of a  mutation/deletion of the  structural  gene 
coding for the a  chain. Structural analysis has shown that  NGI, NG2, and DC1  a 
chains differ substantially from each other (4,  6), implying a  heterogeneity of the Ia 
a  genes as well. Therefore, if mutations (or deletions) of the a  genes have occurred in ROBERTO  S.  ACCOLLA  BRIEF DEFINITIVE REPORT  1057 
the cell variants, they should have been multiple (or extensive in the case of deletions) 
as discussed above for the fl chain-specific genes. 
It might well be that other than specific Ia genes have been affected in the variants. 
It has been shown that biosynthetically labeled Ia molecules are associated intracel- 
lularly to  a  glycoprotein of 32,000  mol wt,  the  intermediate  (In)  (15)  or invariant 
chain  (16).  The biological role of the  In chain  is not  known,  although  it has been 
suggested that it might be implicated in the assembly and/or the transport of the Ia 
heterodimers  to  the  cell  surface.  If this  is  the  case,  a  mutation  affecting the  gene 
coding for the In chain would lead to an altered assembly and/or processing of the Ia 
subunits  and  therefore  to  the  lack  of  detection  by  reagents  that  recognize  the 
assembled  c~-/~ heterodimer.  This  possibility  seems  unlikely  in  the  case  of our  Ia- 
negative variants. In fact, it has been shown that the monoclonals used in this study 
recognize determinants expressed on isolated fl chain (2,  15).  In particular, the Mab 
BT 2.2 is able to immunoprecipitate denaturated/~ chains (15) as well as the/~ chains 
synthesized in Xenopus laevis oocytes injected with m-RNA hybrid selected with a DR~ 
chain specific eDNA clone (17).  Therefore, detection of newly synthesized/~ chains in 
the absence of In chain should be possible in our experimental system. 
As an alternative explanation of the results obtained, we must consider (a) a defect 
of the posttranscriptional  steps leading to a  correct synthesis of the mRNA, specific 
for  NG1,  NG2,  and  DC1  Ia  molecules,  and  (b)  a  defect  of possible  "regulatory" 
gene(s)  controlling  the  transcription  of the  entire  set  of Ia  genes  and  having  the 
capacity to act in "trans" as recently proposed (18). The availability of eDNA probes 
of the  distinct  Ia subunits  will  greatly help  in  clarifying the  mechanisms  through 
which  such variants have been generated and shed more light on the regulation of 
expression of a  genetic system of high biological relevance. 
Summary 
Two monoclonal antibodies, D1-12 and BT 2.2, recognizing two distinct subsets of 
human Ia molecules, NG1 and NG2, respectively, present in all individuals irrespective 
of their HLA-DR phenotype, have been used to immunoselect cell variants from the 
lymphoblastoid cell line Raji. 
Results showed that, irrespective of the monoclonat antibody used for immunose- 
lection, the cell variants analyzed in this study had lost the expression of both D 1-12- 
and  BT  2.2-specific  antigenic  determinants.  Moreover,  the  expression  of antigenic 
determinants specific for a  third  family of Ia molecules, the DC-1  subset, were also 
lost  in  the  cell  variants.  In  contrast,  expression  of HLA  A,  B,  and  C  common 
structures, as recognized by the W6.32 monoclonal antibody, as well as expression of 
surface  immunoglobulins,  were  not  affected.  Possible  mechanisms inducing  such  a 
coordinate loss of expression of several families of human Ia molecules are discussed. 
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